XML 147 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
OTHER EXPENSE (INCOME), NET
 12 Months Ended
Dec. 31, 2019
Other Income and Expenses [Abstract]  
OTHER EXPENSE (INCOME), NET
OTHER EXPENSE (INCOME), NET
Other expense (income), net for the years 2019, 2018 and 2017 consists of:
(in millions)

2019

2018

2017
Gain on the Skincare Sale
 
$
—

 
$
—

 
$
(309
)
Gain on the iNova Sale
 
—

 
—

 
(309
)
Gain on the Dendreon Sale
 
—

 
—

 
(97
)
Loss on the Sprout Sale
 
—

 
—

 
98

Net (gain) loss on other sales of assets
 
(31
)
 
6

 
37

Litigation and other matters
 
1,401

 
(27
)
 
226

Acquired in-process research and development costs
 
41

 
1

 
5

Acquisition-related costs
 
8

 
1

 
—

Other, net
 
(5
)
 
(1
)
 
1

Other expense (income), net

$
1,414

 
$
(20
)
 
$
(348
)

In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter (which is subject to final court approval). In 2018, Litigation and other matters of $27 million includes a favorable adjustment of $40 million related to the Salix legacy litigation matter. In 2017, Litigation and other matters of $226 million includes: (i) $96 million related to the settlement of the Allergan shareholder class actions, (ii) $93 million related to the settlement of the Solodyn® antitrust class actions litigation and (iii) $20 million related to the Mimetogen Pharmaceuticals litigation. These matters and other significant matters are discussed in further detail in Note 21, "LEGAL PROCEEDINGS".
In 2019, Net (gain) loss on other sales of assets includes $20 million related to the achievement of a milestone related to a certain product. In 2019, Acquired in-process research and development costs includes $38 million of in-process research and development costs associated with the upfront payments to enter into certain exclusive licensing agreements.